CIN-107 + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Uncontrolled Hypertension

Conditions

Uncontrolled Hypertension, Chronic Kidney Diseases

Trial Timeline

Apr 29, 2022 → May 2, 2024

NCT ID

NCT05432167

About CIN-107 + Placebo

CIN-107 + Placebo is a phase 2 stage product being developed by AstraZeneca for Uncontrolled Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT05432167. Target conditions include Uncontrolled Hypertension, Chronic Kidney Diseases.

What happened to similar drugs?

4 of 11 similar drugs in Uncontrolled Hypertension were approved

Approved (4) Terminated (0) Active (7)

✅Pegloticase + Methotrexate (MTX)AmgenApproved

✅PegloticaseAmgenApproved

✅Pegloticase + Methotrexate (MTX)AmgenApproved

✅Pegloticase with MTXAmgenApproved

🔄HR17031 injection + insulin glargineJiangsu Hengrui MedicinePhase 3

🔄Baxdrostat + PlaceboAstraZenecaPhase 3

🔄TralokinumabAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05432167	Phase 2	Completed	Apr 29, 2022	May 2, 2024	Uncontrolled Hypertension

Competing Products

17 competing products in Uncontrolled Hypertension

See all competitors

Product	Company	Stage	Hype Score
KHK4563 + KHK4563 + KHK4563 + Placebo	Kyowa Kirin	Phase 2	35
HR17031 injection + insulin glargine	Jiangsu Hengrui Medicine	Phase 3	40
Baxdrostat + Placebo	AstraZeneca	Phase 3	44
Tralokinumab	AstraZeneca	Phase 3	40
Baxdrostat + Placebo	AstraZeneca	Phase 3	40
Benralizumab	AstraZeneca	Phase 3	40
Baxdrostat + Placebo	AstraZeneca	Phase 2	35
Experimental: Tralokinumab	AstraZeneca	Phase 3	40
Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E	AstraZeneca	Phase 1	29
Pegloticase + Methotrexate (MTX)	Amgen	Approved	43
Pegloticase	Amgen	Approved	43
Pegloticase + Methotrexate	Amgen	Phase 3	47
Pegloticase + Methotrexate (MTX)	Amgen	Approved	43
Pegloticase with MTX	Amgen	Approved	43
abrocitinib	Pfizer	Pre-clinical	30
REGN5381 + Placebo	Regeneron Pharmaceuticals	Phase 2	27
SAL0140 + SAL0140 placebo	Shenzhen Salubris Pharmaceuticals	Phase 1	36